List view / Grid view
9 August 2011 | By Boehringer Ingelheim
The pharmaceutical company Boehringer Ingelheim has in the first half of 2011 once again grown in local currency terms compared to the previous year (+ 4 percent). Due to negative foreign exchange effects, consolidation in euros shows growth of 2.6 percent, with total net sales of EUR 6.4 billion against…
4 August 2011 | By Ogilvy Healthworld UK Limited
Pradaxa®1 (dabigatran etexilate) approved...
27 July 2011 | By Boehringer Ingelheim
The CHMP issued a Positive Opinion recommending the approval of Viramune® (nevirapine)...
6 July 2011 | By Boehringer Ingelheim
The www.changemakers.com/morehealth competition launched...
24 June 2011 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly received a positive opinion from the EMA's medicinal committee...
20 June 2011 | By Boehringer Ingelheim
To round off its full-service capabilities for clients, Boehringer Ingelheim is expanding its capacities and capabilities in fill & finish for biopharmaceuticals at their state-of-the-art facility in Biberach, Germany, with a new filling line.
17 June 2011 | By Boehringer Ingelheim
TWYNSTA® leads to prompt and very effective reductions in blood pressure...
16 June 2011 | By Boehringer Ingelheim
For dual-acting glucagon and GLP-1 receptor agonists...
9 May 2011 | By Evotec AG
Twelfth milestone triggers payment of EUR 2 million to Evotec...
3 May 2011 | By OgilvyHealthPR
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…
Yesterday Boehringer Ingelheim formally acquired Amgen’s biopharmaceutical development and manufacturing facility in Fremont, California (USA)...
9 February 2011 | By Boehringer Ingelheim
Announcement covers global technical development and manufacturing for antibody-based therapeutics...
11 January 2011 | By Eli Lilly and Company
Global agreement will lead to joint development of diabetes compounds currently in mid- and late-stage development...
11 November 2005 | By Michael Wiggenhorn, Gerhard Winter, Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University and Ingo Presser, Boehringer Ingelheim
Freeze drying is a widely used method to stabilise protein pharmaceuticals. The stability of proteins and the biological activity can be influenced by several factors, which may lead to conformational changes and to denaturation, aggregation or absorption to surfaces1.
